PT - JOURNAL ARTICLE AU - Krishnamurthy, Hari Krishnan AU - Jayaraman, Vasanth AU - Krishna, Karthik AU - Rajasekaran, Karenah E. AU - Wang, Tianhao AU - Bei, Kang AU - Rajasekaran, John J. AU - Yaskin, Inna AU - Rai, Alex J. AU - Choung, Rok Seon AU - Murray, Joseph A. TI - Antibody Profiling and Prevalence in the US population during the SARS-CoV2 Pandemic AID - 10.1101/2020.04.29.20085068 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.29.20085068 4099 - http://medrxiv.org/content/early/2020/05/05/2020.04.29.20085068.short 4100 - http://medrxiv.org/content/early/2020/05/05/2020.04.29.20085068.full AB - Background Antibody diagnostics play an important role in disease detection and can potentially aid in monitoring of the immune responses to see if an individual has developed immunity. Developing high throughput diagnostics which does not involve handling of infectious material becomes imperative in the case of pandemics such as the recent outbreak of SARS-CoV2.Methods A protein microarray technology was used to detect the plurality of antibody response to four novel antigens namely S1 glycoprotein, Receptor binding domain (RBD), S2 glycoprotein and Nucleoprotein of the novel coronavirus named SARS-CoV2 using serum samples. A DBS card was additionally used to compare its performance with a venipuncture-based serum separator tube (SST) draw.Results The three main subclasses of antibodies IgM, IgA and IgG were analyzed to see the variations in immune responses in the affected population and compared to their microbial RT-PCR based NP swab results. The clinical sensitivity and specificity were determined to be 98.1% and 98.6%. In the matrix comparison study, which would enable patients to test without risk of transmitting the virus, DBS matched with higher than 98% accuracy to a venipuncture-based SST collection.Conclusion Multiplex testing enables higher sensitivity and specificity which is essential while establishing exposure on a population scale. This flexible platform along with a discrete collection methodology would be crucial and broadly useful to scale up testing in current and future pandemics. Minimum sample volume that can be collected using DBS cards can be processed in this multiplex pillar plate format enabling the capacity to provide the reliability of high throughput analyzers while having the ease of collection similar to rapid tests.Competing Interest StatementVibrant America is a commercial lab and performs commercial antibody testing for the novel coronavirus. All of the authors listed in this paper are employees of Vibrant Sciences or Vibrant America, with the exception of AJR IY RSC JAM who are academic/research collaborators.Funding StatementVibrant America is a commercial lab and performs commercial antibody testing for the novel coronavirus. All of the authors listed in this paper are employees of Vibrant Sciences or Vibrant America, with the exception of AJR IY RSC JAM who are academic/research collaborators.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available and are part of the manuscript